JPRN-UMIN000004828
Completed
Phase 1
A phase I clinical study of immune cell therapy with MAGE-A4- or Survivin-specific Th1 cells for patients with refractory virulent tumors - MAGE-A4/Survivin-specific Th1 cell therapy for cancer patients
Department of General Surgery, Hokkaido University Graduated School of Medicine0 sites18 target enrollmentJanuary 7, 2011
Overview
- Phase
- Phase 1
- Intervention
- Not specified
- Conditions
- Refractory cancer patients (MAGE-A4- or Survivin-expressing, non origin-limited) or the patients who refuse standard cancer therapy
- Sponsor
- Department of General Surgery, Hokkaido University Graduated School of Medicine
- Enrollment
- 18
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •1\) Patients with the previous enrollment to clinical trials of cancer immune therapy for MAGE\-A4 in MAGE\-A4\-specific Th1 cell therapy. 2\) Patients with the previous enrollment to clinical trials of cancer immune therapy for Survivin in Survivin\-specific Th1 cell therapy. 3\) Pregnant women or women refused anticonception during the study 4\) Men refused anticonception during the study 5\) Lactating women or women refused lactating during the study 6\) Severe bleeding disorders, meeting the criteria below; PT\<50% APTT\>60sec Fbg\<100mg/dl FDP\>20mg/ml Severe bleeding case judged by an attending physician at the diagnosis 7\) Active infection (HIV, HBV or HCV etc.) 8\) Severe heart disease (NYHA class 3 or 4\) 9\) Autoimmune disease (scleroderma, Sjogren's syndrome, idiopathic thrombocytopenic purpura, multiple sclerosis, rheumatoid arthritis etc.) 10\) Systemic administration of corticosteroid or immunosuppresive drugs during the study (Except local administration, inhaled drugs, and antiphlogistic analgetics). 11\) Patient with impaired mental status in the study. 12\) Inappropriate for study entry judged by an attending physician
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Not Applicable
Phase I study of immuno-Cell therapy for advanced and recurrent esophageal squamous cell carcinomaAdvanced and recurrent esophageal squamous cell carcinomaJPRN-UMIN000007841Toho University5
Completed
Not Applicable
Clinical study of adjuvant immuno-cell therapy for pancreatic cancer curatively resectable.Pancreatic cancerJPRN-C000000414Yokohama City University Hospital10
Completed
Phase 1
A phase I study of combination immunotherapy with five peptides cocktail, CpG, and immune modulators for patients with advanced or metastatic colorectal cancercolorectal cancerJPRN-UMIN000022082Yamaguchi University12
Not yet recruiting
Not Applicable
An exploratory clinical trial of immunotherapy before surgery in stomach cancer casestage I-III stomach cancerJPRN-UMIN000002919JIKEI UNIVERSITY SCHOOL OF MEDICINE50
Unknown
Phase 1
Phase I/II study of adoptive immunotherapy using cytotoxic T cells specific for minor histocompatibility antigen restricted to hematopoietic cells for patients with high-risk leukemia that relapsed following allogeneic hematopoietic stem cell transplantatio1) RAEB, CMML 2) AML or ALL in induction failure or beyond first remission 3) Ph/p190-positive ALL at any stage 4) imatinib-resistant CMJPRN-C000000162Aichi Cancer Center30